These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 9035285)
1. Organ damage is preceded by changes in protein extravasation in an experimental model of multiple organ dysfunction syndrome. Nieuwenhuijzen GA; Knapen MF; Oyen WJ; Hendriks T; Corstens FH; Goris RJ Shock; 1997 Feb; 7(2):98-104. PubMed ID: 9035285 [TBL] [Abstract][Full Text] [Related]
2. Elimination of various subpopulations of macrophages and the development of multiple-organ dysfunction syndrome in mice. Nieuwenhuijzen GA; Knapen MF; Hendriks T; van Rooijen N; Goris RJ Arch Surg; 1997 May; 132(5):533-9. PubMed ID: 9161398 [TBL] [Abstract][Full Text] [Related]
3. Deficiency of complement factor C5 reduces early mortality but does not prevent organ damage in an animal model of multiple organ dysfunction syndrome. Nieuwenhuijzen GA; Meyer MP; Hendriks T; Goris RJ Crit Care Med; 1995 Oct; 23(10):1686-93. PubMed ID: 7587234 [TBL] [Abstract][Full Text] [Related]
4. Interleukin 10 mitigates the development of the zymosan-induced multiple organ dysfunction syndrome in mice. Jansen MJ; Hendriks T; de Man BM; van der Meer JW; Goris RJ Cytokine; 1999 Sep; 11(9):713-21. PubMed ID: 10479408 [TBL] [Abstract][Full Text] [Related]
5. Gradual development of organ damage in the murine zymosan-induced multiple organ dysfunction syndrome. Jansen MJ; Hendriks T; Verhofstad AA; Lange W; Geeraedts LM; Goris RJ Shock; 1997 Oct; 8(4):261-7. PubMed ID: 9329127 [TBL] [Abstract][Full Text] [Related]
6. Improved survival of TNF-deficient mice during the zymosan-induced multiple organ dysfunction syndrome. Volman TJ; Hendriks T; Verhofstad AA; Kullberg BJ; Goris RJ Shock; 2002 Jun; 17(6):468-72. PubMed ID: 12069182 [TBL] [Abstract][Full Text] [Related]
7. A monoclonal antibody against tumour necrosis factor-alpha improves survival in experimental multiple organ dysfunction syndrome. Jansen MJ; Hendriks T; Hermsen R; Van der Meer JW; Goris RJ Cytokine; 1998 Nov; 10(11):904-10. PubMed ID: 9878128 [TBL] [Abstract][Full Text] [Related]
8. Organ damage in zymosan-induced multiple organ dysfunction syndrome in mice is not mediated by inducible nitric oxide synthase. Volman TJ; Goris RJ; van der Jagt M; van de Loo FA; Hendriks T Crit Care Med; 2002 Jul; 30(7):1553-9. PubMed ID: 12130978 [TBL] [Abstract][Full Text] [Related]
9. Inflammatory cytokines in an experimental model for the multiple organ dysfunction syndrome. Jansen MJ; Hendriks T; Vogels MT; van der Meer JW; Goris RJ Crit Care Med; 1996 Jul; 24(7):1196-202. PubMed ID: 8674335 [TBL] [Abstract][Full Text] [Related]
10. [Expression of ubiquitin in the spleen and its influence on the dendritic cell immunomodulation function in multiple organ dysfunction syndrome in mice]. Qu BJ; Lu JY; Liu Q; Wang HW Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2012 Mar; 24(3):149-53. PubMed ID: 22401159 [TBL] [Abstract][Full Text] [Related]
11. Chlorpromazine down-regulates tumor necrosis factor-alpha and attenuates experimental multiple organ dysfunction syndrome in mice. Jansen MJ; Hendriks T; Knapen MF; van Kempen LC; van der Meer JW; Goris RJ Crit Care Med; 1998 Jul; 26(7):1244-50. PubMed ID: 9671376 [TBL] [Abstract][Full Text] [Related]
12. Altered MARCH1 ubiquination-regulated dendritic cell immune functions during the early stage of zymosan-induced multiple organ dysfunction syndrome (MODS) in mice. Li F; Lu JY; Liu Q; Wang HW; Guo H Immunol Lett; 2013 Feb; 150(1-2):105-15. PubMed ID: 23305794 [TBL] [Abstract][Full Text] [Related]
13. Multiple organ dysfunction syndrome: end organ and systemic inflammatory response in a mouse model of nonseptic origin. Shayevitz JR; Miller C; Johnson KJ; Rodriguez JL Shock; 1995 Dec; 4(6):389-96. PubMed ID: 8608394 [TBL] [Abstract][Full Text] [Related]
14. Pentoxifylline does not improve outcome in a murine model for the multiple-organ dysfunction syndrome. Volman TJ; Goris RJ; Hendriks T Intensive Care Med; 2005 May; 31(5):701-8. PubMed ID: 15711975 [TBL] [Abstract][Full Text] [Related]
15. Altered chemokine response in an animal model of multiple organ dysfunction syndrome induced by zymosan. Thomas NJ; Umstead TM; Phelps DS J Pediatr Surg; 2005 Mar; 40(3):464-9. PubMed ID: 15793719 [TBL] [Abstract][Full Text] [Related]
16. Increasing cytotoxic activity and production of reactive oxygen and nitrogen intermediates by peritoneal macrophages during the development of multiple organ dysfunction syndrome in mice. Jansen MJ; Hendriks T; Huyben CM; Tax WJ; van der Meer JW; Goris RJ Scand J Immunol; 1996 Oct; 44(4):361-8. PubMed ID: 8845029 [TBL] [Abstract][Full Text] [Related]
17. Increased expression of matrix metalloproteinases in the murine zymosan-induced multiple organ dysfunction syndrome. Volman TJ; Goris RJ; Lomme RM; DeGroot J; Verhofstad AA; Hendriks T J Pathol; 2004 Aug; 203(4):968-75. PubMed ID: 15259001 [TBL] [Abstract][Full Text] [Related]
18. Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. Rosenstein M; Ettinghausen SE; Rosenberg SA J Immunol; 1986 Sep; 137(5):1735-42. PubMed ID: 3528289 [TBL] [Abstract][Full Text] [Related]
19. The role of tumor necrosis factor in the development of multiple organ failure in a murine model. Burdon D; Tiedje T; Pfeffer K; Vollmer E; Zabel P Crit Care Med; 2000 Jun; 28(6):1962-7. PubMed ID: 10890648 [TBL] [Abstract][Full Text] [Related]
20. GITR gene deletion and GITR-FC soluble protein administration inhibit multiple organ failure induced by zymosan. Galuppo M; Nocentini G; Mazzon E; Ronchetti S; Esposito E; Riccardi L; Di Paola R; Bruscoli S; Riccardi C; Cuzzocrea S Shock; 2011 Sep; 36(3):263-71. PubMed ID: 21654556 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]